LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX · NASDAQ Global Select
-$0.39 today
Vol 0.50M · Avg 0.23M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:LBRX · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$39.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-21.47, tying the income statement back to per-share earnings.
Income Statement
Annual data · 4 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $344.8M | $725.6M | $804.0M |
| Gross Profit | $0 | $0 | $0 | $0 | $10.3B | $8.9B | $7.6B |
| Gross Margin | — | — | — | — | 45.5% | 9.8% | 28.9% |
| Research & Development | $16.7M -67.3% | $51.2M +552.3% | $7.8M +482.8% | $1.3M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $13.7M +0.0% | $13.7M +286.8% | $3.5M +141.4% | $1.5M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $30.4M -53.1% | $64.8M +469.9% | $11.4M +305.0% | $2.8M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $321.0K +252.7% | $91.0K +2175.0% | $4.0K +100.0% | $2.0K | $1.2B | $374.2M | $1.2B |
| EBITDA | -$24.9M +60.5% | -$63.0M -4260.6% | -$1.4M +88.1% | -$12.2M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | — | — | — | — | 10.0% | 5.6% | 46.3% |
| Operating Income | -$30.4M +53.1% | -$64.8M -469.9% | -$11.4M -305.0% | -$2.8M | $10.6B | $12.3B | $14.0B |
| Operating Margin | — | — | — | — | 18.7% | 16.6% | 24.1% |
| Interest Income | $3.9M +127.8% | $1.7M +112.2% | $811.0K +1011.0% | $73.0K | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $0 | $0 -100.0% | $4.8M +124.3% | $2.2M | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | $5.2M +200.8% | $1.7M -66.1% | $5.1M +144.2% | -$11.5M | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | -$25.2M +60.1% | -$63.1M -905.8% | -$6.3M +56.3% | -$14.3M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | — | — | — | — | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $1.0K +0.0% | $1.0K +0.0% | $1.0K +0.0% | $1.0K | $666.8M | $1.3B | -$1.6B |
| Net Income | -$25.2M +60.1% | -$63.1M -905.6% | -$6.3M +56.3% | -$14.3M | $5.0B | $4.9B | $4.8B |
| Net Margin | — | — | — | — | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | -$1 +94.4% | -$18 -907.3% | -$2 +56.3% | -$4 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | -$1 +94.4% | -$18 -907.3% | -$2 +56.3% | -$4 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $25.3M +614.8% | $3.5M -0.0% | $3.5M +0.0% | $3.5M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $25.3M +614.8% | $3.5M -0.0% | $3.5M +0.0% | $3.5M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Design Therapeutics, Inc.
NASDAQ:DSGN
$753.86M
Solid Biosciences Inc.
NASDAQ:SLDB
$591.89M
Annexon, Inc.
NASDAQ:ANNX
$582.64M
Autolus Therapeutics plc
NASDAQ:AUTL
$411.19M
Aura Biosciences, Inc.
NASDAQ:AURA
$396.75M
DBV Technologies S.A.
NASDAQ:DBVT
$381.21M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$352.15M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$300.81M
Altimmune, Inc.
NASDAQ:ALT
$239.62M
Korro Bio, Inc.
NASDAQ:KRRO
$126.76M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does LBRX generate?
LB Pharmaceuticals Inc Common Stock (LBRX) reported $0.00 of revenue in fiscal 2025.
Is LBRX profitable?
LB Pharmaceuticals Inc Common Stock (LBRX) reported -$25,205,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.